AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04868474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training program and decision aid
Description: 1) a one-time, in-person, 2.5-hour training program encouraging participating GPs to present quitting smoking with a quit aid as the default choice to their eligible patients, and 2) access to an electronic decision aid that presents available quit aids. The 2.5-hour training program consists of: 1.5 hours of didactic teaching, with information about pharmacologic quit aids, electronic cigarettes, presenting quitting as a default choice, the decision aid, and a video of a model consultation. This is followed by 1 hour of role plays to practice presenting quitting as a default choice using the decision aid.
Study NCT04868474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Refresher course
Description: A 45-minute refresher training about smoking cessation that does not aim to change GP behaviour. It will include the same information about pharmacologic quit aids and electronic cigarettes.
Study NCT05321628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool
Description: Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.
Study NCT05321628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Cognitive Behavioural Therapy (iCBT)
Description: iCBT, as described above, using only the traditional, detailed therapist manual.
Study NCT04947553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05 (dextromethorphan-bupropion)
Description: AXS-05 tablets, taken twice daily
Study NCT04947553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study NCT05266196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seclidemstat
Description: Treatment assigned as per parent protocol
Study NCT05103033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach for Mental Health (SAIA-MH)
Description: The 5 steps of SAIA-MH include: (1) cascade analysis to visualize treatment cascade drop-offs and prioritize areas for system improvements; (2) process mapping to identify modifiable facility-level bottlenecks; (3) identification and implementation of modifications to improve system performance; (4) assessment of modification effects on the cascade; and (5) repeated analysis and improvement cycles.
Study NCT05103033 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attentional Placebo Control
Description: Facilities randomized to attentional placebo control will attend a 1-week in-person training which will include the same minimum staff above for SAIA-MH. This training will focus on reviewing data collection tools, ethics, mental health stigma and burnout for mental health professionals. Following the 1-week in person training, attentional placebo control facilities will receive regular supervision following the same schedule as SAIA-MH focused on reviewing data collection tools.
Study NCT05662358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
Study NCT05662358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
Study NCT06122610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
Description: SPECT/CT will be performed after first cycle of Lutathera® treatment
Study NCT05662358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo weekly
Study NCT05662358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral placebo weekly
Study NCT06122610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon Emission Tomography / CT (PET/CT)
Description: PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
Study NCT06122610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-Dotatate
Description: Standard of care administration of radioactive drug for PET/CT
Study NCT06122610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Description: Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Study NCT06479863 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pozelimab/Cemdisiran
Description: Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks
Study NCT05720520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technological education method
Description: Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
Study NCT06555640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR10624 Injection
Description: Drug: DR10624 injection
Study NCT06555640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo
Study NCT06779773 — intervention group
Intervention type: DRUG
Intervention: Avacincaptad pegol (ACP)
Description: intravitreal injection
Study NCT06781957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins Subcutaneos
Description: Gonadotropins s.c. single dose
Study NCT06781112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
Description: Induction chemotherapy with PD-1 inhibitor combined with TPF regimen, administered every 3 weeks: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and PD-1 inhibitor ( 200mg).~All patients received 3 cycles of induction therapy followed by radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment, Q3W. The cisplatin in the synchronous chemoradiotherapy regimen is administered once a week, with a dose of 40mg/m2 per dose, and the total dose of cisplatin does not exceed 100mg/m2. For patients who cannot tolerate cisplatin during synchronous radiotherapy and chemotherapy, cisplatin may not be combined.
Study NCT06782048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo by mouth once each day for a total of 14 days.
Study NCT06782048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrvinium
Description: Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
Study NCT05064839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bony scintigraphy
Description: Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
Study NCT06782048 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood biomarkers analyses
Description: Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.
Study NCT06782048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood biomarkers analyses
Description: Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.
Study NCT06782048 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oesophagogastroduodenoscopy (OGD) and biopsy
Description: Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.
Study NCT04825262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose based on CYP3A5 genotype
Study NCT05703412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition-FOCUS mHealth Intervention
Description: tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
Study NCT05703412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check-In
Description: Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
Study NCT06561425 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG5101
Description: Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
Study NCT05982431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: 60-minutes exercise program, three times a week on alternate days for 12 successive weeks
Study NCT05982431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinsio taping
Description: One full strip of kinesiology taping tape and one half-length strip were needed for the kinesiology taping application
Study NCT05982431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo Kinsio taping
Description: One full strip of kinesiology taping tape and one half-length strip were needed for the placebo kinesiology taping application
Study NCT05208307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Given IV
Study NCT05208307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT05208307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT06115148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding
Description: Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
Study NCT06115148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Water will be consumed as described during the Fasting Arm.
Study NCT05486741 — intervention group
Intervention type: OTHER
Intervention: Optical cehernce tomography
Description: OCT macula and disc
Study NCT05765981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R09b
Description: VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
Study NCT05562011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caretaker Device placement
Description: a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
Study NCT06782048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oesophagogastroduodenoscopy (OGD) and biopsy
Description: Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.
Study NCT05526703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064, D701, placebo of D012
Description: Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
Study NCT05526703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D012, placebo of D064, placebo of D701
Description: Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
Study NCT06782048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gastric juice, saliva and stool collection and analyses
Description: Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.
Study NCT06782048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric juice, saliva and stool collection and analyses
Description: Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.
Study NCT00548106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: partially hydrolyzed whey
Description: Total infant feeding by study formula.
Study NCT00548106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: partially hydrolyzed whey
Description: Total infant feeding by study formula.
Study NCT00548106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nan HA
Description: Total infant diet by study formula.
Study NCT05351398 — intervention group
Intervention type: DRUG
Intervention: PDO group
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
Study NCT05351398 — intervention group
Intervention type: DRUG
Intervention: Traditional group
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
Study NCT06780735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The margin-positive rate using the localization technique
Description: Localization of breast cancer using indocyanine green fluorescence (ICG-F)
Study NCT05991921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section.
Study NCT05991921 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Plasebo-Fake TENS
Description: Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
Study NCT04533477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructing forked corpus spongiosum (FCS)
Description: During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.
Study NCT04533477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine standardized surgery
Description: When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
Study NCT04533477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine standardized surgery
Description: When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
Study NCT04783142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High-fiber, low-protein diet
Description: Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
Study NCT04783142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low-fiber, high-protein diet
Description: Diet will consist of less than 15g fiber and greater than 18% of calories from protein
Study NCT06780774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine, Vitamins, Minerals and Botanical Blend
Description: Blend containing 120mg of caffeine, vitamins, minerals and botanical extracts in capsule form.~Other Names: Active Treatment
Study NCT04075370 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological Testing
Description: Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A\&B and COWA over time.
Study NCT05308186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory stimulation
Description: The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
Study NCT05308186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory and tactile stimulations
Description: The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
Study NCT05013086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.48 GBq of 177Lu-AB-3PRGD2
Description: accepted intravenous injection of 177Lu-AB-3PRGD2
Study NCT04852627 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisk walking
Description: Walking
Study NCT05532631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
Study NCT05532631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines